On the Immunological Consequences of Conventionally Fractionated Radiotherapy.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsAlfonso, Juan Carlos L
Papaxenopoulou, Lito A
MetadataShow full item record
AbstractEmerging evidence demonstrates that radiotherapy induces immunogenic death on tumor cells that emit immunostimulating signals resulting in tumor-specific immune responses. However, the impact of tumor features and microenvironmental factors on the efficacy of radiation-induced immunity remains to be elucidated. Herein, we use a calibrated model of tumor-effector cell interactions to investigate the potential benefits and immunological consequences of radiotherapy. Simulations analysis suggests that radiotherapy success depends on the functional tumor vascularity extent and reveals that the pre-treatment tumor size is not a consistent determinant of treatment outcomes. The one-size-fits-all approach of conventionally fractionated radiotherapy is predicted to result in some overtreated patients. In addition, model simulations also suggest that an arbitrary increase in treatment duration does not necessarily result in better tumor control. This study highlights the potential benefits of tumor-immune ecosystem profiling during treatment planning to better harness the immunogenic potential of radiotherapy.
CitationiScience. 2020 Feb 11;23(3):100897. doi: 10.1016/j.isci.2020.100897.
AffiliationBRICS, Braunschweiger Zentrum für Systembiologie, Rebenring 56,38106 Braunschweig, Germany.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- A minimal modeling framework of radiation and immune system synergy to assist radiotherapy planning.
- Authors: Montaseri G, Alfonso JCL, Hatzikirou H, Meyer-Hermann M
- Issue date: 2020 Feb 7
- Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications.
- Authors: Esposito A, Criscitiello C, Curigliano G
- Issue date: 2015 Nov
- Norm- and hypo-fractionated radiotherapy is capable of activating human dendritic cells.
- Authors: Kulzer L, Rubner Y, Deloch L, Allgäuer A, Frey B, Fietkau R, Dörrie J, Schaft N, Gaipl US
- Issue date: 2014 Oct
- External beam radiation dose escalation for high grade glioma.
- Authors: Khan L, Soliman H, Sahgal A, Perry J, Xu W, Tsao MN
- Issue date: 2016 Aug 19
- Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
- Authors: Lunsford LD, Flickinger JC, Larson D
- Issue date: 1997